Skip to content

Drug formulations in life sciences transactions

Browse this blog post

On Tuesday 25 May 2021, Allen & Overy IP associate Tine Carmeliet chaired a presentation with IP partner Keren Livneh, IP associate Megan McMellon and M&A associate Zara Sproul on “Drug formulations in life sciences transactions”. 

Drug formulations are incredibly valuable to pharmaceutical businesses; however, they often get overlooked during transactions.  This can create risk for both the seller and buyer of the assets. Our speakers covered the importance of drug formulations, the common pitfalls buyers and sellers can fall into during a transaction, whether you should assign or licence the formulation, and practical tips relating to both routes.